Use and tolerability of newer antipsychotics and antidepressants: A chart review in a paediatric setting

Pharmacy World and Science

Volumn 30, Issue 1, 2008, Pages 44-50

  Alacqua, Marianna ^a   Trifirò, Gianluca ^a,c   Arcoraci, Vincenzo ^a   Germanò, Eva ^a   Magazù, Angela ^a   Calarese, Tiziana ^a   Di Vita, Giuseppa ^b   Gagliano, Catalda ^b   Spina, Edoardo ^a,c  

^a UNIVERSITY OF MESSINA   (Italy)

^b OASI RESEARCH INSTITUTE IRCCS   (Italy)

^c IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

Author keywords

Adolescents; Adverse drug reactions; Atypical antipsychotics; Children; Italy; Selective serotonin reuptake inhibitors

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CITALOPRAM; CLOZAPINE; FLUOXETINE; FLUVOXAMINE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; ZIPRASIDONE;

ADOLESCENT; AMENORRHEA; AMINOTRANSFERASE BLOOD LEVEL; ANXIETY DISORDER; ARTICLE; ASTHENIA; AUTISM; BRADYKINESIA; CHILD; CHILD PSYCHIATRY; CLINICAL STUDY; CONDUCT DISORDER; CONVERSION DISORDER; DATA COLLECTION METHOD; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; EDEMA; ENURESIS; EPISTAXIS; FAINTNESS; FEMALE; GALACTORRHEA; HEADACHE; HEPATIC VOLUME; HUMAN; HYPERPHAGIA; HYPERPROLACTINEMIA; HYPERSALIVATION; INCREASED APPETITE; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MENTAL DEFICIENCY; MENTAL DISEASE; MOOD DISORDER; NAUSEA; NUCHAL RIGIDITY; OBSESSIVE COMPULSIVE DISORDER; OUTCOME ASSESSMENT; PANIC; PATIENT COMPLIANCE; PATIENT MONITORING; POLYDIPSIA; POLYURIA; PRESCRIPTION; PROLACTIN BLOOD LEVEL; PSYCHOSIS; RASH; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SEDATION; SIDE EFFECT; SOMNOLENCE; STATISTICAL ANALYSIS; STEREOTYPY; TACHYCARDIA; TIC; UNJUSTIFIED CRYING; VERTIGO; WEIGHT GAIN; XEROSTOMIA;

ADOLESCENT; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHILD; CITALOPRAM; DRUG UTILIZATION REVIEW; FEMALE; FLUOXETINE; HUMANS; HYPERPROLACTINEMIA; ITALY; MALE; MEDICAL RECORDS; MENTAL DISORDERS; PAROXETINE; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES; RISPERIDONE; SERTRALINE; TREATMENT OUTCOME;

EID: 36448958326     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-007-9139-6     Document Type: Article

References (29)

1. Schirm E, Tobi H, Zito JM, de Jong-van den Berg LT. Psychotropic medication in children: a study from the Netherlands. Pediatrics 2001;108:E25.
2. Zito JM, Safer DJ, dosReis S, Gardner JF, Boles M, Lynch F. Trends in the prescribing of psychotropic medications to preschoolers. JAMA 2000;283:1059-60.
3. 'T Jong GW, Eland IA, Sturkenboom MC, van den Anker JN, Stricker BH. Unlicensed and off label prescription of drugs to children: population based cohort study. BMJ 2002;324:1313-4.
4. Turner S, Nunn AJ, Fielding K, Choonara I. Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr 1999;88:965-8.
5. Findling RL, McNamara NK. Atypical antipsychotics in the treatment of children and adolescents: clinical applications. J Clin Psychiatry 2004;65:30-44.
6. Cheng-Shannon J, McGough JJ, Pataki C, McCracken JT. Second-generation antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 2004;14:372-94.
7. Henry CA, Steingard R, Venter J, Guptill J, Halpern EF, Bauman M. Treatment outcome and outcome associations in children with pervasive developmental disorders treated with selective serotonin reuptake inhibitors: a chart review. J Child Adolesc Psychopharmacol 2006;16:187-95.
8. Wilens TE, Biederman J, Kwon A, et al. A systematic chart review of the nature of psychiatric adverse events in children and adolescents treated with selective serotonin reuptake inhibitors. J Child Adolesc Psychopharmacol 2003;13:143-52.
9. Hazell P, O'Connell D, Heathcote D, Henry D. Tricyclic drugs for depression in children and adolescents. Cochrane Database Syst Rev 2002;CD002317.
10. Geller DA, Hoog SL, Heiligenstein JH, et al. Fluoxetine Pediatric OCD Study Team. Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial. J Am Acad Child Adolesc Psychiatry 2001;40:773-9.
11. Keller MB, Ryan ND, Strober M, et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 2001;40:762-72.
12. Masi G, Toni C, Mucci M, Millepiedi S, Mata B, Perugi G. Paroxetine in child and adolescent outpatients with panic disorder. J Child Adolesc Psychopharmacol 2001;11:151-7.
13. Walkup J, Labellarte M, Riddle MA, et al. Treatment of pediatric anxiety disorders: an open-label extension of the research units on pediatric psychopharmacology anxiety study. J Child Adolesc Psychopharmacol 2002;12:175-88.
14. Committee on Safety of Medicines. Selective serotonin reuptake inhibitors: overview of regulatory status and CSM advice relating to major depressive disorder (MDD) in children and adolescents including a summary of available safety and efficacy data. Available from: http://www.medicines.mhra. gov.uk/ourwork/monitorsafequalmed/safetymessages/ssrioverview_101203.htm (accessed 19 April 2006).
15. Ma J, Lee KV, Stafford RS. Depression treatment during outpatient visits by U.S. children and adolescents. J Adolesc Health 2005;37:434-42.
16. US Food and Drug Administration, Suicidality in Children and Adolescents Being Treated With Antidepressant Medications (2004) October 15. Available from: http://www.fda.gov/cder/drug/antide pressants/ssripha200410.htm (accessed 19 April 2006).
17. Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviours. JAMA 2004;292:338-43.
18. Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
19. Arango C, Parellada M, Moreno DM. Clinical effectiveness of new generation antipsychotics in adolescent patients. Eur Neuropsychopharmacol 2004;14:471-9.
20. Gagliano A, Germano E, Pustorino G, et al. Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications. J Child Adolesc Psychopharmacol 2004;14:39-47.
21. Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004;114:634-41.
22. McConville BJ, Sorter MT. Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses. J Clin Psychiatry 2004;65:20-9.
23. Worrel JA, Marken PA, Beckman SE, Ruehter VL. Atypical antipsychotic agents: a critical review. Am J Health Syst Pharm 2000;57:238-55.
24. Hellings JA, Zarcone JR, Valdovinos MG, Reese RM, Gaughan E, Schroeder SR. Risperidone-induced prolactin elevation in a prospective study of children, adolescents, and adults with mental retardation and pervasive developmental disorders. J Child Adolesc Psychopharmacol 2005;15:885-92.
25. Masi G, Cosenza A, Mucci M. Prolactin levels in young children with pervasive developmental disorders during risperidone treatment. J Child Adolesc Psychopharmacol 2001;11:389-94.
26. Toren P, Ratner S, Laor N, Weizman A. Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents. Drug Saf 2004;27:1135-56.
27. Horen B, Montastruc JL, Lapeyre-Mestre M. Adverse drug reactions and off-label drug use in paediatric out patients. Br J Clin Pharmacol 2002;54:665-70.
28. Stigler KA, Potenza MN, McDougle CJ. Tolerability profile of atypical antipsychotics in children and adolescents. Paediatr Drugs 2001;3:927-42.
29. Diler RS, Avci A. Selective serotonin reuptake inhibitors in children and adolescents. Swiss Med Wkly 2002;132:470-7.